VivoSeq
Oncology

Recurrent Diffuse Large B-Cell Lymphoma

15

Pipeline Programs↗

4

Active Trials↗

11

Companies Involved↗

Recurrent Diffuse Large B-Cell Lymphoma is an emerging landscape with 15 programs across 11 companies. The most active players are Sanofi, Novartis, Teva.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

15/100

Mech. Concentration

11/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 1Novartis logo

Novartis

1 program

Phase 1Teva logo

Teva

2 programs

Phase 2Roche logo

Roche

2 programs

Phase 2A

Avyxa

1 program

Phase 2Genmab logo

Genmab

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

16programs
Small molecule956%
Monoclonal antibody425%
Cell therapy213%
Antibody–drug conjugate16%

Modality classified for 100% of 16 pipeline programs.

Analysis

Trial Status

4

clinical trials

Recruiting3 · 75%
Not yet recruiting1 · 25%

Clinical Trials

Trial Activity

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Recruiting·CCity of Hope Medical Center·Phase 2·NCT05672251·36 enrolled
A Phase 2 Study of Odronextamab in Relapsed/ Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Before and After Chimeric Antigen Receptor (CAR) T-Cell Therapy
Recruiting·UUniversity of California, Davis·Phase 2·NCT06854159·34 enrolled
A Phase I Trial of Lymphodepletion Intensification With Low Dose Total Body Irradiation With Dose Expansion for Standard-of-Care Tisagenlecleucel in Patients With Large B-Cell Lymphoma
Not yet recruiting·—·Phase 1·NCT07676877·18 enrolled
A Phase 2 Study of Epcoritamab (Epco) Plus Physician's Choice of Platinum-Containing Chemotherapy Pre-Autologous Hematopoietic Cell Transplantation (AutoHCT) Followed by Post-AutoHCT Epco Consolidation/ Maintenance in Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL)
Recruiting·UUniversity of California, Davis·Phase 2·NCT06905509·25 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)